Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral hypoglycaemic agents. An update.

A C Asmal, A Marble

    Drugs
    |July 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Oral hypoglycaemic agents aid diabetes management, particularly in early, overweight cases. Long-term benefits and risks require further study, emphasizing careful patient selection for optimal outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

    Canadian journal of surgery. Journal canadien de chirurgie·2022
    Same author

    Relation of Control of Diabetes to Vascular Degenerative Lesions in Young Diabetics.

    Transactions of the American Clinical and Climatological Association·2011
    Same author

    Tropical disease as seen in an Army general hospital in the zone of the interior.

    The air surgeon's bulletin·2010
    Same author

    Liver function tests in neurosyphilitic patients with induced vivax malaria of Pacific and Mediterranean origin.

    The Journal of laboratory and clinical medicine·2010
    Same author

    Islet-cell tumor of the pancreas with hyperinsulinism; a report of six cases.

    The New England journal of medicine·2010
    Same author

    Relapses following delayed treatment of naturally induced vivax malaria of Pacific origin.

    Science (New York, N.Y.)·2010
    Same journal

    Ecnoglutide: First Approvals.

    Drugs·2026
    Same journal

    The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

    Drugs·2026
    Same journal

    Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

    Drugs·2026
    Same journal

    Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

    Drugs·2026
    Same journal

    Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

    Drugs·2026
    Same journal

    Relacorilant: First Approval.

    Drugs·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Metabolic Diseases

    Background:

    • Oral hypoglycaemic agents have been available for decades but their precise mechanisms and roles in diabetes mellitus management remain debated.
    • They are often used as adjuncts for non-insulin-dependent diabetes unresponsive to diet, with varying success rates.
    • Understanding their efficacy and long-term impact is crucial for patient care.

    Purpose of the Study:

    • To review the current understanding of oral hypoglycaemic agents' mode of action and clinical utility.
    • To evaluate their effectiveness in different patient subgroups and treatment scenarios.
    • To discuss the long-term benefits, risks, and the importance of patient selection in managing diabetes mellitus.

    Main Methods:

    • Literature review and synthesis of existing research on oral hypoglycaemic agents.

    Related Experiment Videos

  • Analysis of factors influencing initial effectiveness, such as disease duration, weight, and baseline glucose levels.
  • Examination of evidence regarding long-term efficacy, toxicity, and drug interactions.

    • Main Results:

    • Initial effectiveness is highest in patients with recent-onset ( < 5 years), overweight, non-insulin-dependent diabetes with fasting glucose < 200 mg/dl.
    • Successful transition from insulin to oral agents is more likely if daily insulin dose is < 20-30 units.
    • While short-term glycemic control is established, long-term benefits in reducing complications are not yet substantiated.
    • Sulfonylureas' long-term effects may stem from enhanced insulin sensitivity, not just insulin secretion.
    • Significant adverse effects are uncommon, but hypoglycemia is a risk with sulfonylureas and lactic acidosis with biguanides.
    • Second-generation sulfonylureas offer no clear advantages over older ones; gliclazide's microvascular benefits need more research.

    Conclusions:

    • Careful patient selection is paramount for maximizing efficacy and minimizing toxicity of oral hypoglycaemic agents.
    • Long-term benefits of these agents in preventing diabetes complications require further investigation.
    • Ongoing vigilance for chronic toxicity and drug interactions is essential, especially when long-term efficacy is difficult to quantify.